The Role of Dopaminergic Agents in Improving Quality of Life in Major Depressive Disorder
The Role of Dopaminergic Agents in Improving Quality of Life in Major Depressive Disorder
复制标题
DOI：
10.1007/s11920-009-0076-z
复制
发表时间：
2009-12-01
影响因子：
6.7
通讯作者：
Rapaport, Mark Hyman
中科院分区：
文献类型：
--
作者：
IsHak, Waguih William;Davis, Michael;Rapaport, Mark Hyman
重度抑郁症（MDD）患者在治疗前的生活质量（QOL）大大降低。即使患者处于缓解期，这种缺陷也会持续存在;因此，需要进行干预以改善QOL。本文综述了抑郁症患者的生活质量损害及损害的代价，并总结了多巴胺能药物对抑郁症患者生活质量影响的经验性文献。通过MEDLINE检索过去35年（1974-2009）的研究，使用关键词“生活质量”、“重度抑郁症”和“重度抑郁症”以及“多巴胺能”、“安非他酮”或“莫达非尼”。“共有47项研究被纳入本次审查。简要概述了生活质量和抑郁症之间的关系，其次是多巴胺能药物的化学，作用机制，使用和试验进行调查代理商的生活质量的影响。初步证据表明，多巴胺能药物可能对MDD患者的生活质量有积极影响。需要前瞻性、随机、双盲、安慰剂对照研究来扩展这些发现。
Quality of life (QOL) is greatly diminished in patients with major depressive disorder (MDD) before treatment. This deficit persists even when patients are in remission; thus, interventions are needed to improve QOL. This article reviews QOL impairment in MDD and the cost of impairment, then summarizes the empiric literature on the effects of dopaminergic agents on QOL in patients with MDD. Studies were identified through a MEDLINE search from the past 35 years (1974-2009) using key terms "quality of life," "major depression," and "major depressive disorder," and "dopaminergic," "bupropion," or "modafinil." A total of 47 studies were included in this review. A brief overview of the relationship between QOL and MDD is presented, followed by a review of dopaminergic agent chemistry, mechanism of action, use, and trials conducted to investigate agents' effects on QOL. Preliminary evidence suggests dopaminergic agents may have a positive effect on QOL for patients with MDD. Prospective, randomized, double-blind, placebo-controlled studies are needed to extend these findings.